Publication | Open Access

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial

Hematological MalignancyFlt3 InhibitorMedicineHematologyClinical TrialsMyeloid NeoplasiaPharmacotherapyOncologyRadiation OncologyHealth Sciences